Collectively, these findings indicate that targeting PAK1 by pharmacological inhibitor IPA-3 could suppress tumor growth and metastatic behavior of ESCC cells and that it likely acts through blocking the Raf1/MEK1/ERK signaling pathway. The gene discussed is MAP2K1; the disease is esophageal squamous cell carcinoma.